Grifols (NASDAQ:GRFS) is one of the 10 Overlooked Growth Stocks to Buy Now.
Grifols (NASDAQ:GRFS) is one of the overlooked growth stocks to buy now. On March 17, Grifols unveiled proof-of-concept data from its Chronos-PD program, showing that molecular changes associated with Parkinson’s disease/PD can be detected up to 12 years before a clinical diagnosis. The study analyzed over 2,600 longitudinal plasma samples using AI and advanced proteomics. This deep profiling allowed researchers to track the evolution of distinct proteins over time, potentially establishing an early-warning system for a disease that currently lacks early detection biomarkers.
The research identified reproducible early molecular signals, including the discovery of a major modulation in the CXCL12-cell adhesion molecules-integrin axis. This signaling network is responsible for governing leukocyte trafficking and blood-brain barrier integrity, both of which are central to the neuroinflammation seen in PD. By uncovering these distinct molecular patterns, Grifols (NASDAQ:GRFS) aims to support future efforts in patient stratification and precision medicine, providing a window for intervention before significant dopamine-producing brain cells are lost.
Pixabay/Public Domain
Chronos-PD is part of a broader Grifols initiative that uses a proprietary library of over 100 million plasma samples connected to real-world data. The study validated early biomarkers across five independent cohorts. Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer, noted that the platform’s ability to search for the earliest signs of disease could accelerate the development of new diagnostics and disease-modifying therapeutics for various public health challenges beyond Parkinson’s.
Grifols (NASDAQ:GRFS) is a healthcare company that deals in plasma-derived medicines through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company provides plasma-derived therapeutics, diagnostic systems, hospital healthcare solutions, and integrated pharmaceutical services.
While we acknowledge the risk and potential of GRFS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GRFS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.